Keros Therapeutics, Inc. KROS
Set alert
10.90 USD +0.14 +1.30%
As of Nov 3, 10:28 AM ET
10.78 Day range 11.11
9.69 52-week range 22.55
- YTD
- -46.46%
- 1 year
- -28.38%
- Open
- 10.78
- Prev close
- 10.76
- Mkt cap
- 217.11M
- Vol
- 18.34K
- Avg vol
- 188.53K
- EPS
- -3.15
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.78
- High
- 11.11
- Forward P/E
- -3.00
- Beta
- 1.24
- Short ratio
- 5.28
- Inst. own
- 100.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 55.00
- 200-d avg
- 53.85
- 1y target
- 43.55
2Y chart
Events in this range
- Nov 6, 2024Earnings: -1.41; estimate -1.26; surprise -11.9%
- Dec 12, 2024Downgrade: William Blair · Outperform → Market Perform
- Dec 13, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 13, 2024Rating: Scotiabank · Sector Outperform → Sector Outperform
- Dec 16, 2024Downgrade: Guggenheim · Buy → Neutral
- Dec 16, 2024Rating: Oppenheimer · Outperform → Outperform
- Dec 23, 2024Rating: Truist Securities · Buy → Buy
Signals (83)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 30, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 27, 2026 | 1 week ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 14, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 29, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| SMA: Bullish | Jul 15, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
Newest 20 of 83.
Key statistics
- Market cap
- 693.49M
- Enterprise value
- 178.44M
- Trailing P/E
- 0.00
- Forward P/E
- -3.00
- PEG ratio
- 0.00
- Price / sales
- 1065.26
- Price / book
- 1.26
- EPS (TTM)
- -5.22
- Beta
- 1.24
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 651.00K
- Revenue growth
- 4750.00%
- Free cash flow
- -89.32M
- Total cash
- 530.68M
- Total debt
- 19.29M
- Return on equity
- -43.82%
- Shares outstanding
- 40.51M
- Short % of float
- 7.39%
- 50-day average
- 55.00
- 200-day average
- 53.85
Analyst view
Consensus: buy
Buy
Price target (mean) 43.55 +299.5% upside
Now 10.90
- Target (low)
- 23.00
- Target (mean)
- 43.55
- Target (high)
- 76.00
Ratings (0m) 14 11 buy · 3 hold · 0 sell
- Strong buy3
- Buy8
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.51.
Financials — quick view
KROS Revenue — quarterly 0
KROS Net income — quarterly -28.71M
KROS EPS — quarterly -1.45
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -1.26 | -1.41 | -0.15 | -11.90% |
| Aug 7, 2024 | Jun 1, 2024 | -1.23 | -1.25 | -0.02 | -1.63% |
| Aug 7, 2024 | Jun 1, 2024 | -1.23 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -1.31 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -1.31 | -1.21 | +0.10 | +7.63% |
| Feb 28, 2024 | Dec 1, 2023 | -1.38 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | Truist Securities | main | Buy | Buy |
| Dec 16, 2024 | Oppenheimer | main | Outperform | Outperform |
| Dec 16, 2024 | Guggenheim | down | Buy | Neutral |
| Dec 13, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 12, 2024 | William Blair | down | Outperform | Market Perform |
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kerostx.com
News
- Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
- Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)
- KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
- Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial
- Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
- Keros Therapeutics Doses First Patient In Phase 2 Clinical Study Of Rinvatercept In Patients With Duchenne Muscular Dystrophy
- Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
- Keros Therapeutics Reveals $5M Share Repurchase Authorization
- Keros Therapeutics Announces $5 Million Share Repurchase Authorization
- Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
Your note
Sign in to keep a note on KROS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GORDON CARL L | Director | Sale | Aug 12, 2024 | 0 |
| ORBIMED ADVISORS, L.L.C. | Unknown | Sale | Aug 12, 2024 | 0 |
| REGNANTE KEITH C | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 2, 2023 | 0 |
| SEEHRA JASBIR | Chief Executive Officer | Conversion of Exercise of derivative security | Apr 6, 2023 | 252,856 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.09% | 4,899,134 | 83.87M | Sep 29, 2024 |
| Blackrock Inc. | 6.50% | 2,632,608 | 45.07M | Sep 29, 2024 |
| Alkeon Capital Management LLC | 4.68% | 1,897,601 | 32.49M | Sep 29, 2024 |
| Vanguard Group Inc | 4.58% | 1,856,418 | 31.78M | Sep 29, 2024 |
| Darwin Global Management, Ltd. | 3.76% | 1,523,732 | 26.09M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 3.74% | 1,514,505 | 25.93M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.37% | 961,347 | 16.46M | Sep 29, 2024 |
| ACAP Strategic Fund | 2.31% | 933,991 | 15.99M | Sep 29, 2024 |
| Price (T.Rowe) New Horizons Fund | 2.17% | 877,880 | 15.03M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.87% | 756,550 | 12.95M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 1.63% | 661,229 | 11.32M | Oct 30, 2024 |
| Fidelity Select Portfolios - Health Care | 1.60% | 650,000 | 11.13M | Oct 30, 2024 |